SOLICITATION NOTICE
A -- Development of a hybridoma cell line for monoclonal antibodies to human butyrylcholinesterase and development of an LC-MS/MS method for assessing organophosphorus compound exposure
- Notice Date
- 8/3/2012
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-Q-14951
- Archive Date
- 9/2/2012
- Point of Contact
- Vallerie M Redd, Phone: 770-488-2845
- E-Mail Address
-
gfj3@cdc.gov
(gfj3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Center for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH), Division of Laboratory Science (DLS), intends to award a sole source purchase order to University of Nebraska Medical Center (Oksana Lockridge Laboratory), 985950 Nebraska Medical Center, Omaha, NE 68198-5950 for the procurement of services of development of a hybridoma cell line for monoclonal antibodies to human butyrylcholinesterase (BChE) and development of an LC - MS/MS method for assessing organophosphorus compound exposure. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 611310, Colleges, Universities and Professional Schools. The purpose of this acquisition is to purchase cultures of a hybridoma cell line that make monoclonal antibodies specific to human BChE, as well as to purchase a written procedure describing a method for distinguishing the aged biomarkers of exposure to a variety of organophosphorus compound classes. Oksana Lockridge's lab is the only lab in the world that has the ability to generate large amounts of highly purified human BChE. BChE is a highly specific biomarker of exposure to organophosphorus (OP) compounds including organophosphorus nerve agents (OPNAs) and OP pesticides, and CDC currently has developed an emergency response methods for assessing human exposure to nerve agent by measuring PONA-BChE adducts. Currently, distribution of the CDC method to collaborators and public health labs within the Laboratory Response Network is limited by the high cost of the antibodies used for capturing the biomarker BchE in clinical blood samples. Oksana Lockridge's lab has developed the only method to generate large quanties of highly purified, enzymatically active, conformationally intact BChE. Large amounts of purified BChE are needed in order to develop and grow hybridoma cell lines that produce monoclonal antibodies specific for enzymatically active BChE. Oksana Lockridge's lab also has the required experience in monoclonal antibody development, knowledge of maintaining and storing live hybridoma cultures, access to organophosphorus compound inhibited serum samples, and expertise in the development of mass spectrometry based methods for measuring protein biomarkers of exposure to OPNA and other OP compounds. All of these capabilities are required to successfully develop human BChE antibodies that can be used in the CDC OPNA-BChE adduct method and also develop methods for distinguishing the aged biomarkers of exposure to a wide variety of organophosphorus compounds including nerve agents, pesticides, and jet engine lubricant additives. They are leading internationally recognized experts in cholinesterases and in all aspects of assessing human exposure to organophosphorus compounds. They are the only lab that is able to generate large amounts of pure BChE, develop a panel of potential monoclonal antibodies specific for BChE, and then asses the performance of those antibodies for measuring exposure to OP nerve agents. UNMC has demonstrated an ability to quickly respond to all requests made with regards to this research area. To ensure a timely and high-quality deliverable, UNMC is the only company that can be used. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to the University of Nebraska Medical Center. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by August 18, 2012. The Contracting Officer will not respond to verbal request. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Vallerie Redd by email at gfj3@cdc.gov and reference solicitation number 2012-Q-14951 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-Q-14951/listing.html)
- Place of Performance
- Address: Vendor's Facility, Omaha, Nebraska, United States
- Record
- SN02826054-W 20120805/120803234908-b82a33c5df56b9867b7183cc008e3d07 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |